Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins

Group 1: GLP-1 Weight Loss Market - Novo Nordisk and Eli Lilly are competing in the GLP-1 weight loss market, with Novo Nordisk's pill version of Ozempic intensifying the rivalry [1] - Wall Street is heavily focused on pharmaceutical companies leading the GLP-1 charge, indicating significant investor interest in this sector [3] Group 2: Intuitive Surgical's Market Position - Intuitive Surgical has 11,106 surgical robots in the market as of the end of 2025, reflecting a 12% increase from 9,902 at the end of 2024 [4] - The number of surgeries performed with the da Vinci system rose 18% year over year, demonstrating strong demand for robotic surgery [4] Group 3: Investment Considerations - Intuitive Surgical's price-to-earnings ratio is currently 61, which is below its five-year average of 71, suggesting the stock may be relatively cheap historically [5] - The company is expected to have compelling long-term growth opportunities as demand for surgical robots continues to rise [6] - The integration of artificial intelligence in surgical procedures could position Intuitive Surgical favorably for future advancements [7] Group 4: Growth Potential - Intuitive Surgical is identified as a growth stock, appealing to aggressive growth investors in the healthcare sector [9] - The stock may be considered cheap relative to its historical valuation, making it an attractive option for growth-focused investors [9]